Pharma firms protest UK gov't. pricing decision

Drugmakers are speaking out against a decision by the U.K.'s Department of Health to end a deal allowing some of them to increase prices to make up money they lost when a previous agreement was suspended in 2007. The Association of the British Pharmaceutical Industry has objected to both the decision on the accord, known as the Pharmaceutical Price Regulation Scheme, and the refusal to share information showing how it was reached. Novartis and Pfizer have already said they plan to scale back U.K. operations. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.